# Low Dose IL-2 for the Treatment of Crohn's Disease

> **NCT04263831** · PHASE1,PHASE2 · RECRUITING · sponsor: **Boston Children's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Interleukin-2 (aldesleukin).

## Key facts

- **NCT ID:** NCT04263831
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04263831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04263831, "Low Dose IL-2 for the Treatment of Crohn's Disease". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04263831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*